Fulgent Genetics (FLGT) EBT (2015 - 2026)

Fulgent Genetics has disclosed EBT across 12 years of filings, most recently posting -$29.7 million for Q2 2026.

• In Q2 2026, EBT fell 37.97% year-over-year to -$29.7 million; the TTM figure through Jun 2026 stood at -$92.5 million (down 54.55% YoY), while the FY2025 annual figure was -$70.0 million, down 34.78% from the prior year.
• EBT came in at -$29.7 million for Q2 2026 at Fulgent Genetics, down from -$26.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $202.0 million in Q1 2022 to a low of -$145.2 million in Q4 2023.
• Average EBT over 5 years is -$9.3 million, with a median of -$14.4 million recorded in 2023.
• Year-over-year, EBT jumped 290.44% in 2023 and slumped 370.15% in 2024.
• Over 5 years, EBT stood at -$33.5 million in 2022, then plunged by 333.91% to -$145.2 million in 2023, then surged by 94.46% to -$8.0 million in 2024, then slumped by 263.88% to -$29.3 million in 2025, then dropped by 1.42% to -$29.7 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$29.7 million in Q2 2026, -$26.0 million in Q1 2026, and -$29.3 million in Q4 2025.